These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 22596228

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 24. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 12; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 25. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Dec 12; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 26. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.
    J Neuropathol Exp Neurol; 2012 Jul 12; 71(7):604-17. PubMed ID: 22710964
    [Abstract] [Full Text] [Related]

  • 27. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 28. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
    Zhang Y, Wright C, Flores A.
    J Med Case Rep; 2018 Jul 01; 12(1):187. PubMed ID: 29960601
    [Abstract] [Full Text] [Related]

  • 29. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
    Gibelin N, Daelman L, Goulipian S, Wynckel A, Chaunu MP, Tourbah A.
    Rev Neurol (Paris); 2014 Jan 01; 170(1):48-50. PubMed ID: 24139244
    [No Abstract] [Full Text] [Related]

  • 30. Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
    Hodel J, Outteryck O, Verclytte S, Deramecourt V, Lacour A, Pruvo JP, Vermersch P, Leclerc X.
    AJNR Am J Neuroradiol; 2015 Dec 01; 36(12):2296-302. PubMed ID: 26316568
    [Abstract] [Full Text] [Related]

  • 31. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F, Newsome SD, Viscidi R.
    Mol Cell Probes; 2015 Feb 01; 29(1):54-62. PubMed ID: 25483260
    [Abstract] [Full Text] [Related]

  • 32. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 33. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical?
    Arnaud FX, Hissene A, Métivier D, Dutasta F, Berets O, N'guema B, A'teriitéhau C, Baccialone J, Potet J.
    J Neuroradiol; 2012 Oct 10; 39(4):267-70. PubMed ID: 22341620
    [Abstract] [Full Text] [Related]

  • 34. Natalizumab-induced progressive multifocal leukoencephalopathy.
    Thaker AA, Schmitt SE, Pollard JR, Dubroff JG.
    Clin Nucl Med; 2014 Jul 10; 39(7):e365-6. PubMed ID: 24152618
    [Abstract] [Full Text] [Related]

  • 35. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 10; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 36. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 37. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 38. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 39. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
    Tortorella C, Direnzo V, D'Onghia M, Trojano M.
    Neurology; 2013 Oct 15; 81(16):1470-1. PubMed ID: 24127190
    [No Abstract] [Full Text] [Related]

  • 40. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ, Sorbello A, Kortepeter C, Scarazzini L.
    Ann Neurol; 2014 Jan 15; 75(1):108-15. PubMed ID: 24242357
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.